Abiraterone acetate plus prednisone and ADT is associated with improved health-related quality of life compared with ADT plus placebo among patients with metastatic castration-naïve prostate cancer.

Conferences

In the first study to evaluate patient-reported outcomes from the NRG Oncology/RTOG 0415 trial, treatment with hypofractionated radiation therapy offers similar health-related quality of life (HRQoL) outcomes in one-third less treatment time compared with conventional radiation therapy in men with early stage, low-risk prostate cancer, reported researchers at the 58th Annual Meeting of the Amer

Read More

High-dose stereotactic body radiotherapy (SBRT) for men with newly-diagnosed low- or intermediate-risk prostate cancer results in shorter treatment times, low severe toxicity, and excellent cancer control rates, according to research presented at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO) in Boston, MA (Sept 25-26).

-----

Read More

Patients with metastatic castrate resistant prostate cancer treated with enzalutamide (ENZ) may be more likely to experience central nervous system adverse events and fatigue than those who receive a combination of abiraterone acetate and prednisone (AA+P), according to the results of a poster presented at the American Society of Clinical Oncology Annual Meeting (June 3-7, 2016; Chicago, IL).

Read More

News

Abiraterone acetate plus prednisone and ADT is associated with improved health-related quality of life compared with ADT plus placebo among patients with metastatic castration-naïve prostate cancer.
A recent study suggests that circulating tumor cell count as a response measure of prolonged survival may be a meaningful endpoint for early-phase metastatic castration-resistant prostate cancer.
In a recent study, researchers compared the effects of a novel therapy versus surveillance alone in patients with oligorecurrent prostate cancer.
Metastatic castration-resistant prostate cancer that progresses after enzalutamide treatment may be effectively managed with bipolar androgen therapy.

Research in Review

Research suggests that age can impact the risk of disease progression in low-risk prostate cancer managed with active surveillance, published in the Journal of Clinical Oncology (June 2017;35[17]:1898-1904).

-----

Related Content

Read More

Current National Comprehensive Cancer Network (NCCN) guidelines and Gleason scores cannot reliably stratify patients with risk of prostate cancer for the presence or absence of pathogenic germline variants, according to keynote presentation at the 2017 ASCO Annual Meeting (June 2-6, 2017; Chicago, IL).

-----

Related Content

Read More

Groundbreaking results of a trial have shown that the combination of a new drug with androgen deprivation therapy (ADT) significantly improves overall survival (OS) and radiographic progression-free survival (PFS) in patients with high-risk metastatic hormone-naïve prostate cancer, presented at the 22017 ASCO Annual Meeting (June 2-6, 2017; Chicago, IL).

-----

Read More

A diagnostic magnetic resonance imaging (MRI) scan followed by an MRI-guided biopsy strategy is more cost-effective than an invasive transrectal ultrasound for detecting prostate cancer, according to research published in Radiology (published online May 2017; doi:10.1148/radiol.2017162181).

-----

Related Content

Read More

Subscribe to Prostate Cancer